Transition from anti-CD20 therapies to fumarates as a treatment strategy: A multicenter, retrospective observational experience
{{output}}
We present real-world data on patients switching from anti-CD20s to fumarates for various motivations in this retrospective observational study of 43 patients from three multiple sclerosis centers. Recurrent infections on anti-CD20s were the most common reason... ...
